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Abstract: Hemoglobin S in homozygous state or in combination with one of the structural variants 
of Hb D-Punjab, Hb O-Arab, Hb C or β
that is characterized by chronic hemolytic anemia and tissue injury second
chronic  hypercoagulable  state  in  SCD  has  been  established  with  the  increased  risk  of 
thromboembolic complications  in these patients. The goal of present review is to survey of the 
literature related to thromboembolic events and genet
these events in SCD patients with focus on studies from Mediterranean countries. Also, this review 
covers  the  pathogenesis  of  hypercoagulability  and  alteration  in  the  components  of  hemostasis 
system.
Introduction: The Hb S that results from substitution 
of valine for glutamic acid at position 6 of β
chain  was  the  first  hemoglobin  variant  to  be 
discovered.
1 This  abnormal  hemoglobin  is  the  most 
clinically  important  structural  variant  of  hemoglobin 
with  highest  frequency  in  Africa,  Saudi  Arabia,  and 
India.
1,2 Sickle  cell  disease  (SCD)  results  from  the 
homozygous  state  of  the  mutation,  or  a  compound 
heterozygous state with one of structural variants of Hb 
D-Punjab, Hb O-Arab, Hb C or β-thalassemia mutation 
in  the  other  β-gene.
2 This  group  of  disorders 
characterized by the  polymerization  of deoxygenated 
hemoglobin S into rigid rodlike polymers, causing the 
sickling of the erythrocyte.
3
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Hemoglobin S in homozygous state or in combination with one of the structural variants 
Arab, Hb C or β-thalassemia mutation results in sickle cell disease (SCD) 
that is characterized by chronic hemolytic anemia and tissue injury second
chronic  hypercoagulable  state  in  SCD  has  been  established  with  the  increased  risk  of 
thromboembolic complications  in these patients. The goal of present review is to survey of the 
literature related to thromboembolic events and genetic risk factors involved in the manifestation of 
these events in SCD patients with focus on studies from Mediterranean countries. Also, this review 
covers  the  pathogenesis  of  hypercoagulability  and  alteration  in  the  components  of  hemostasis 
The Hb S that results from substitution 
of valine for glutamic acid at position 6 of β-globin 
chain  was  the  first  hemoglobin  variant  to  be 
abnormal  hemoglobin  is  the  most 
clinically  important  structural  variant  of  hemoglobin 
with  highest  frequency  in  Africa,  Saudi  Arabia,  and 
Sickle  cell  disease  (SCD)  results  from  the 
homozygous  state  of  the  mutation,  or  a  compound 
e with one of structural variants of Hb 
thalassemia mutation 
This  group  of  disorders 
characterized by the  polymerization  of deoxygenated 
hemoglobin S into rigid rodlike polymers, causing the 
The β
S mutation has been found to  be in linkage 
disequilibrium, with five distinct, typical (common) β
globin  gene  cluster  haplotypes.  Four  of  these 
haplotypes  are  known  as  African  haplotypes  (Bantu, 
Benin, Senegal, and Cameroon), the fif
Indian haplotype, which was originally described in the 
eastern  oases  of  Saudi  Arabia  and  among  the  tribal 
Adivasi population of India.
hematological manifestations of sickle cell anemia are 
varied and are influenced by other pleiotropic effects of 
the haplotype background linked to the β
SCD is known as a hypercoagulable state in which 
various  hemostatic  systems  both  in  steady  state  and 
during  vaso-occlusion  are  perturbed  with  increased 
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Hemoglobin S in homozygous state or in combination with one of the structural variants 
thalassemia mutation results in sickle cell disease (SCD) 
that is characterized by chronic hemolytic anemia and tissue injury secondary to vasooclusion. A 
chronic  hypercoagulable  state  in  SCD  has  been  established  with  the  increased  risk  of 
thromboembolic complications  in these patients. The goal of present review is to survey of the 
ic risk factors involved in the manifestation of 
these events in SCD patients with focus on studies from Mediterranean countries. Also, this review 
covers  the  pathogenesis  of  hypercoagulability  and  alteration  in  the  components  of  hemostasis 
mutation has been found to  be in linkage 
disequilibrium, with five distinct, typical (common) β-
globin  gene  cluster  haplotypes.  Four  of  these 
haplotypes  are  known  as  African  haplotypes  (Bantu, 
Benin, Senegal, and Cameroon), the fifth is the Arab-
Indian haplotype, which was originally described in the 
eastern  oases  of  Saudi  Arabia  and  among  the  tribal 
Adivasi population of India.
4 The clinical severity and 
hematological manifestations of sickle cell anemia are 
ed by other pleiotropic effects of 
the haplotype background linked to the β
S gene.
5,6
SCD is known as a hypercoagulable state in which 
various  hemostatic  systems  both  in  steady  state  and 
occlusion  are  perturbed  with  increased Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
activation  of  the  coagulation  system  and  platelets, 
thrombin generation, and occurrence of thrombosis.
7-10
Cerebral venous and sinus thrombosis (CVST): The 
most  important  cause  of  stroke  in  SCD  patients  is 
large-vessel  cerebral  arterial  complication  that  might 
be the result of abnormal adhesive and procoagulant 
properties of RBC, which produce endothelial damage, 
secondary  intimal  proliferation,  and  thrombosis.
10-12
The  incidence  of  cerebro-vascular  complications  in 
SCD is 5 to 10% (13). In 11% of sickle cell anemia 
patients stroke is occurred by age 20, with infarction 
mainly  in  the  internal  carotid  and  middle  cerebral 
arteries.
14
Association  between  SCD  and  cerebral 
thromboembolic  events  has  been  investigated  in 
several  studies.  Alli  et  al
15 reported  the  presence  of 
skull bone infarction crisis and deep vein thrombosis in 
a  boy  with  homozygous  sickle  cell  anemia  (SCA). 
Also, in individuals with sickle cell trait (SCT) cerebral 
infarction and stroke is not rare and there are several 
case reports related to the incidence of stroke in these 
individuals.
16-19 There  are  few  studies  from 
Mediterranean  countries  reported  the  occurrence  of 
CVST and stroke in SCD patients. Sidani et al
20 have 
reported the existence of venous and sinus thrombosis 
and stroke in a Lebanese young homozygous sickle cell 
patient.  However,  in  this  patient  the  presence  of 
proteins C, S, antithrombin III, factor V Leiden (FVL), 
and prothrombin  mutations as well as anticardiolipin 
antibodies were negative.
20 Also, a 25-year-old French 
SCD  patient  with  cerebral  vein  thrombosis  and 
bilateral thalamic infarcts has been reported.
21 Further, 
the report of Ozu et al
22 indicated the occurrence of 
sinus thrombosis and thalamic infarcts in a 2-year-old 
child from Turkey. In addition, Radhakrishnan et al
16
reported  the  presence  of  stroke  in  two  young  adult 
sickle cell trait individuals from Libya. 
Pulmonary embolism and deep vein thrombosis: A 
link between hypercoagulability in SCD patients and 
pulmonary  hypertension  (PHT),  increased  pulmonary 
artery pressure and pulmonary vascular resistance, has 
been established.
7,23 Pulmonary hypertension occurs in 
approximately 30% of adult patients with SCD and is a 
risk  factor  for  early  death.
24 In  studies  using 
echocardiograms  of  patients  with  SCA  who  were 
examined at referral centers the prevalence of PHT was 
20 to 30%. In autopsy studies, approximately 75% of 
patients  with  SCA  present  histological  evidence  of 
PHT.
25
Hemolysis  has  been  identified  as  one  of  the 
potential  driving  forces  of  the  hypercoagulable  state 
and  developing PHT in  SCD.
23,26 However, Beers  et 
al
27 did  not  detect  a  significant  difference  in 
haemolysis  between  patients  with  and  without  PHT 
and did not find a direct link of the hypercoagulable 
state to mild SCD related PHT.
A  mechanism  related  to  nitric  oxide  (NO) 
scavenging by free hemoglobin has been implicated in 
the  pulmonary  arterial  disease of  sickle  cell  anemia. 
Hemolytic  anemia  through  hemolysis  and  release  of 
hemoglobin  into  plasma  which  consumes  NO  and 
release arginase into plasma leads to resistance to NO-
dependent  vasodilatory  effects.  This  is  an  important 
process in the development of PHT and shortened life 
expectancy  in  patients  with  SCD.
25,28 Bunn  et  al
29
reviewed the literature related to the influence of NO 
depletion  by  plasma  hemoglobin  in  the 
microcirculation on the pathogenesis of PHT in SCD 
patients. They concluded that pulmonary hypertension 
per se was not a major cause of death in sickle cell 
patients and  therapies  that  might  enhance  the 
availability of NO to the vasculature have thus far been 
ineffective and/or toxic. 
In  a  large  case-control  study  on  515  hospitalized 
black patients with thromboembolism and Hb S and C 
and 555 black controls revealed that persons with SCT 
experienced approximately a 2-fold increased risk of 
venous  thromboembolism  (VTE)  compared  with 
persons  with  the  wild-type  genotype,  Hb  AA.  This 
increased  risk  was  observed  both  for  idiopathic  and 
provoked VTE as well as for first and recurrent VTE. 
In  addition,  pulmonary  embolism  (PE)  risk  (without 
DVT)  was  significantly  increased  (approximately  4-
fold)  among  those  with  SCT,  whereas  the  risk  of  a 
DVT  (without  PE)  was  not  significantly  increased.
30
The increased risk of VTE is attributed to subclinical 
sickling of red cells.
30
Results  of  autopsy  of  12  SCD  patients  suggested 
that  pulmonary  thromboemboli  may  be  a  late 
complication  of  PHT  and  an  in  situ  thrombotic 
arteriopathy underlies the development of PHT in most 
patients  with  sickle  cell  disease.
29 Small  vessel 
thrombosis is  one of underlying cause  of pulmonary 
hypertension (PHT) among patients with SCD (31) and 
an association between thromboembolism and PHT has 
been  suggested.
32 Staser  et  al
33 reported  a  rare 
phenomenon of calcified pulmonary thromboembolism 
in an African American boy with SCD.
Higher  prevalence  of  pulmonary  embolism  in 
African American SCD patients below 40 years of age 
(0.44%)  compared  to  non  SCD  African  Americans 
(0.12%)  has  been  reported.
34 Clinical  assessment 
and/or autopsy findings at the time of death among 141 
adults with sickle cell disease (SCD) over a 25-year 
period revealed that PHT is the leading cause of death 
(26.2%) and thromboembolism was the fifth symptom 
leading to death in these patients. In another study with 
the goal of determining the most common pathologic Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
findings in autopsy cases with sickle cell lung disease 
indicated the high percentage of PHT (33.3%) in these 
autopsy  samples.
35 The  risk  of  thromboembolic 
complications  in  SCD  patients  appears  to  be  higher 
following splenectomy.
7,36
Genetic  of  Thromboembolism:  Venous 
thromboembolism is believed to be caused by genetic 
and  acquired  risk  factors.  The  inherited 
hypercoagulable syndromes primarily affect veins, and 
only  rarely  cause  arterial  thrombosis.  The  acquired 
hypercoagulable  states,  such  as  the  antiphospholipid 
antibody syndrome, are more commonly implicated in 
arterial stroke.
37
The  role  of  inherited  thrombophilia  in  the
pathogenesis  of  sickle  cell  thromboses  has  been 
reported in few studies. In these studies the frequency 
of  thrombophilic  mutations  of  FVL,  prothrombin 
G20210A,  and  methylenetetrahydrofolate  reductase 
(MTHFR) C677T and their association with incidence, 
and recurrence  of  thromboembolism  among  SCD 
patients have been examined.
The factor V Leiden mutation is caused by a single 
point  mutation  at  nucleotide  1691,  leading  to  an 
Arg/Gln  amino  acid  exchange  at  this  position  is  the 
most  frequent  inherited  risk  factor  for 
thromboembolism in Caucasians with a prevalence of 
5%  in  the  general population.
13 Higher  frequency of 
this  mutation  in  β-thalassemia  patients  and  its 
association with deep venous thrombosis and cerebral 
venous and sinus thrombosis has been reported.
38-40
There are many studies reported the low frequency 
of  thrombophilic  mutations  in  SCD  patients  and  the 
lack of association between these mutations and risk of 
thromboembolism. Helley et al
13 in a large sample of 
SCD  patients  from  Africa  indicated  the  absence  of 
FVL  mutation  in  these  patients.  However,  the  gene 
frequency  of  the  FVL  in  black  SCD  subjects  from 
West  Indies  and  Maghrib  were  2.5  and  1.1%, 
respectively.  They  concluded  that  in  sub-Saharan 
African  SCD  patients  FVL  is  not  an  additional  risk 
factor  for  thrombosis.
13 Also,  In  African  American 
with SCD this mutation was uncommon and was not 
found to be responsible for stroke in these patients.
41,42
Further,  in  the  study  of  Wright  et  al
43 among  SCD 
patients from Jamaica no FVL mutation was found in 
these patients. However, a significant reduction in the 
median activated protein C resistance ratio compared 
to controls was observed in their study. Moreira Neto 
et al
44 reported no prothrombin G20210A mutation in 
SCD  patients  from  Brazil.  The  frequency  of 
heterozygous FVL mutation was 1.8% in their studied 
patients. In another study from Brazil, Andrade et al
45
studied the prevalence of the FVL mutation, MTHFR 
C677T polymorphism, and prothrombin gene variant in 
SCD patients. It was reported no significant difference 
between SCD patients and the control population for 
the prevalence of the studied thrombophilic mutations. 
However,  among  nine  studied  SCD  patients  with 
vascular  complications  of  stroke  or  deep  vein 
thrombosis they found only one patient to be a carrier 
for  FVL.  Also,  Kordes  et  al
46 reported  no  medical 
history of deep vein thrombosis in two SCA patients 
homozygous for FVL mutation from Iraq. Fawaz et al
47
have compared the  prevalence of  FVL mutation and 
prothrombin gene variant in SCD patients and controls 
from Eastern Saudi Arabia. Their study revealed that 
there is no association between the mutations and SCD. 
Furthermore,  Zimmerman  et  al
48 reported  no 
association  between  thrombophilic  mutations  of 
MTHFR C677T and platelet glycoprotein IIIa (GPIIIa) 
C1567T with SCD.
In contrast, in spite of the moderate prevalence of 
FVL mutation (2.97-5.5%) among normal population 
of Iran
49,50 a high prevalence of FVL mutation (14.3%) 
among Iranian SCA patients
9 has been found with a 
significant association between this mutation and SCA 
with odds ratios (OR) of 6.5 (95% confidence intervals 
[CI]  1.19–35.33,  p  =  0.03).  In  addition,  increased 
prevalence  of  the  FVL  mutation  in  SCT  individuals 
and sickle/β-thalassemia  patients was not statistically 
different from controls (OR=3.84, 95% CI 0.49–29.9, p 
= 0.19 and OR=3.77, 95% CI 0.31– 45.9, p = 0.29, 
respectively).
9 Also,  in  a  study  from  Brazil  it  was 
suggested that MTHFR C677T might be a risk factor 
for vascular complications in SCD.
44
According to  the literature, there have been three 
studies  of  inherited  risk  factors  of  venous 
thromboembolism  in  SCD  patients  from  Southern 
Mediterranean  countries
51-53 which  report  high 
prevalence of thrombophilic mutations in SCD patients 
and their association with thromboembolism in these 
patients.  Among  Lebanese  sickle/β
0-thalassemia 
patients, a high prevalence of thrombophilic mutations 
of  FVL  (42%),  homozygous  and  heterozygous 
MTHFR  C677T  (59%),  and  prothrombin  G20210A 
(8%)  has  been  reported.
51 In  this  report  sickle-β-
thalassemia  patients  were  5.24  and  4.39  times  more 
likely to have FVL mutation as compared to the normal 
controls  and  thalassemia  intermedia  patients, 
respectively (p <0.05). Also, the presence of extensive 
large  vessel  thrombosis  in  a  sickle/β
0-thalassemia 
patient from Lebanon doubles heterozygous for FVL 
and  MTHFR  C677T  (homozygous  for  FVL  and 
heterozygous for MTHFR has been reported.
52 Further, 
in a sickle cell anemia patient from Israel, Koren et al
53
reported the recurrent of cerebrovascular accident and 
deep  venous  thrombosis.    Activated  protein  C 
resistance due to FVL heterozygous and heterozygocity 
for  the  MTHFR  C677T  have  been  diagnosed  and Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
suspected to be the risk factors that contribute to the 
development of the deep vein thrombosis in this SCA 
patient.
Pathogenesis  of  Hypercoagulability:  The 
pathogenesis of hypercoagulability is considered to be 
multifactorial.  Altered  components  of  hemostasis 
system  in  SCD  have  been  suggested.  Low  plasma 
levels  of  protein  C,  protein  S,  and  antithrombin  III, 
elevated  plasma  levels  of  thrombin-antithrombin 
(TAT) complexes, prothrombin fragment 1+2 (F1+2), 
D-dimer  complexes,  and  circulating  antiphospholipid 
antibodies,  platelet  activation  during  vaso-occlusive 
crisis,  abnormal  external  exposure  of 
phosphatidylserine  (PS)    and  adherence  of  sickle 
erythrocytes to the vascular endothelium, reducing NO 
level  in  the  presence  of  hemolytic  anemia,  and 
increased tissue factor expression have been detected 
in  SCD  patients.
8,12,36 These  abnormalities  of 
hemostatic system in SCD are leading to increase risk 
of thrombosis.
Coagulation Factors and Inhibitors: El-Hazmi et al
54
reported significantly reduced levels of proteins C and 
S  in  SCD  patients  with  the  highest  prevalence  of 
deficiency in patients with a severe form of disease and 
frequent  episodes  of  crisis.  Lower  levels  of  the 
naturally  occurring  anticoagulants  protein  S  and 
protein C which are found in SCD patients could be 
attributed to either hemostatic abnormalities or hepatic 
dysfunction. Liesner et al
55 reported that children with 
SCD have a reduction in levels of the majority of the 
coagulation inhibitors (protein C and S) and increased 
thrombin  generation  (thrombin-antithrombin 
complexes  and  prothrombin  fragment  1+2  in  the 
steady-state  which  is  only  partially  reversed  by 
transfusion. Onyemlukwe et al
56 described significantly 
lower  level  of  serum  AT-III  in  patients  with  SCD 
compared  to  controls.  Bayazit  et  al
57 in  a  survey  of 
SCA  anemia  patients  in  a  steady  state  from  Turkey 
found a significant lower level of protein C and AT 
levels in patients with SCA compared to controls. Also, 
they reported non significant lower levels of protein S 
in the patients than in the controls. They suggested that 
both hemostatic abnormalities and hepatic dysfunction 
contribute  to  low  levels  of  natural  coagulation 
inhibitors in SCA patients.
Abnormal Structure of Red Blood Cells Membrane:
External  exposure  of  phosphatidylserine  has  been 
implicated  in  the  pathogenesis  of  adhesion  of 
erythrocytes  to  endothelium  in  SCD.  During 
deoxygenation,  the  amino  phospholipids  and 
phosphatidylethanolamine,  are  exposed  to  external 
membrane of red blood cells (RBC) and permanently 
fixed in irreversibly sickled cells leading to promote 
coagulation  of  red  blood  cells  and  platelets.
58 The 
enzyme  of  scramblase  in  a  Ca 
++ dependent  process 
which  is  modified  by  sulphydryl  is  involved  in  the 
translocation  of  PS  from  inner  to  outer  layer  of 
membrane.
59 The  increased  oxidative  stress  in 
hemoglobinopathies
60 increases  sulphydryl 
modification and external exposure of PS. This process 
is a signal for RBC removal in apoptosis and a docking 
site for proteins involved in coagulation processes.
61- 64
Altered  structure  of  RBC  membrane  in  sickle  cell 
disease  due  to  external  exposure  of  PS  in  the  outer 
membrane increases adhesion of sickle erythrocytes to 
endothelial  cells  and  microvascular  occlusion.  This 
alteration  decreases  red  blood  cell  survival  by 
increased  splenic  clearance  of  PS  positive 
erythrocytes.
65 Annexin V through calcium dependent 
mechanism binds to anionic phospholipids (primarily 
PS) exposed at external membrane layer. A high level 
of  normal  binding  of  annexin  V  to  erythrocytes  in 
sickle  cell  disease  has  been  demonstrated.    Painful 
vasoocclusive  crises  may  partly  result  from  these 
abnormal  adhesive  RBCs  interacting  with  adhesion 
receptors  on  endothelia.
66 Setty  et  al
67 revealed  a 
significant  positive  correlation between  PS  positive 
RBC and adhesion to vascular endothelium. 
In SCD patients  the  presence of  Arab-Indian  and 
Senegal haplotype backgrounds of β
S gene compared to 
African haplotypes of Benin, Bantu and Cameroon are 
associated with higher levels of Hb F and amelioration 
of  anemia.
4,5 The  benefit  of  Hb  F  effect  in  SCD 
patients has been shown that higher levels of F cells 
have  a  concomitant  decrease  in  the  numbers  of 
microvesicles and PS-positive cells.
68 The association 
between  in  vivo  PS  positive  RBC  and  thrombin 
generation in SCD patients has been demonstrated by 
Setty  et  al.
69 Westerman  et  al
70 study  indicated  that 
posphatidylserine positive RBC are a significant source 
of PS (+) vesicles in SCA and the levels of circulating 
RBC-derived  vesicles  are  increased  in  SCA.  They 
reported  a  linkage  between  vesicle  levels  and 
activation  of  thrombin.  The  correlation  between 
subpopulations of PS (+) erythrocytes and the risk of 
stroke  in  patients  with  SCD  has  also  been 
demonstrated.
71 Overall,  the  role  of  RBC  in  the 
coagulation activation has been shown that includes a 
significant correlation between the numbers of RBCs 
with  external  exposure  of  phosphatidylserine  with 
plasma  markers  of  thrombin  generation,  such  as 
prothrombin  fragment  1+2  (F1+2),  D-dimer  and 
plasmin- antiplasmin  complexes.  However,  such 
association  was  not  detected  between 
phosphatidylserine-positive  platelets  and  markers  of 
thrombin generation.
68,69Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Elevation of Tissue Factor Expression: Tissue factor 
(TF) is a transmembrane glycoprotein that is involved 
in  the  activation  of  prothrombin  and  thrombin 
formation.
72 Endothelial cells through expression of TF 
initiate  coagulation.  Significant  elevation  of  TF  in 
blood  monocytes  and  circulating  endothelial  cells  of 
SCD  patients  has  been  demonstrated  that  could  be 
responsible for activation of the coagulation system in 
SCD patients.
72,73
The mechanisms of activation TF are 1) increased 
heme  levels  through  hemolysis  which  induces  TF 
expression  on  the  surface  of  endothelial  cells,
36  2) 
ischemia-reperfusion injury (hypoxia/reoxygenation),
74
3)  increased  levels  of  soluble  CD40  ligand  through 
activation of platelets and exposure of CD40 ligand on 
their  surface.
75 In  addition,  the  over  expression  of 
markers  of  endothelial  activation such as endothelial 
adhesion  proteins  (intercellular  adhesion  molecule-1 
[ICAM-1],  E  selectin  [ELAM-1],  P  selectin  and 
vascular cell adhesion molecule-1 [VCAM-1] has been 
reported in SCD.
76
The utility of anticoagulant therapy as prophylaxis 
in  hemolytic  anemias  such  as  SCD  and  novel 
approaches,  including  anti-hemolytic  therapies, 
hemoglobin  scavengers  and  NO  donors  have  been 
suggested  that  could  decrease  the  occurrence  of 
thrombotic complications.
36
Conclusions: There  are several evidences that prove 
the multifactorial pathogenesis of hypercoagulability in 
SCD  that  include  disturbing  red  blood  cell 
phospholipids  membrane  asymmetry,  abnormal 
activation  of  endothelial  cells  and  other  blood  cells. 
The  hypercoagulable  state in  SCD  patients  could  be 
more  complicated  in  the  presence  of  inherited  and 
acquired risk factors of thrombosis. Future studies on 
the  influence  of  thrombotic  risk  factors  on  the 
incidence of thromboembolic events in SCD patients 
could elucidate the actual risk of thromboembolism in 
these patients.  
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